TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34374766

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 6797

Group type: COMPARATOR
Intervention: Dronedarone vs. Placebo
Number of subjects: 6797
Study: 34717741

Group type: EXPERIMENTAL
Intervention: Liposuction
Number of subjects: 405

Group type: COMPARATOR
Intervention: Complex decongestive therapy (CDT)
Number of subjects: 405
Study: 33151313

Group type: EXPERIMENTAL
Intervention: Baseline serum neurofilament light concentration
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Highest vs lowest baseline serum neurofilament light tertiles
Number of subjects: 308

Group type: COMPARATOR
Intervention: Highest neurofilament tertile
Number of subjects: 308

Group type: COMPARATOR
Intervention: Lowest neurofilament tertile
Number of subjects: 308
Study: 35766355

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) targeting the globus pallidus internus/externus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotactic brain grafting
Number of subjects: 0
Study: 33899971

Group type: EXPERIMENTAL
Intervention: Endurance Training (END)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both END and RT
Number of subjects: 35
Study: 35508923

Group type: EXPERIMENTAL
Intervention: 100 g beetroot (272 mg NO3‐)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 g beetroot (544 mg NO3‐)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 g beetroot (816 mg NO3‐)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200-ml solution containing 1000 mg potassium nitrate (KNO3)
Number of subjects: 24
Study: 34404091

Group type: EXPERIMENTAL
Intervention: Local vibration therapy (VT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 32493288

Group type: EXPERIMENTAL
Intervention: Cisplatin low cumulative dose (≤150 mg/m2)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Cisplatin intermediate cumulative dose (151-250 mg/m2)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Cisplatin high cumulative dose (>250 mg/m2)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Overall population (all cumulative doses)
Number of subjects: 779
Study: 34182575

Group type: EXPERIMENTAL
Intervention: Scabies (91 adults, 103 children)
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Control group (participants without skin disease)
Number of subjects: 1655
Study: 34639692

Group type: EXPERIMENTAL
Intervention: Fitness app usage (experimental group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no fitness app usage)
Number of subjects: 66
Study: 32396914

Group type: EXPERIMENTAL
Intervention: Lavender oil application
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no lavender oil)
Number of subjects: 68
Study: 33100327

Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemoradiotherapy (CRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Capecitabine-based chemoradiotherapy (CRT)
Number of subjects: 60
Study: 35103059

Group type: EXPERIMENTAL
Intervention: Bromhexine hydrochloride (8 mg 3 times per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 32104959

Group type: EXPERIMENTAL
Intervention: Palatal augmentation prostheses (PAP)
Number of subjects: 20
Study: 35554758

Group type: EXPERIMENTAL
Intervention: Immuno-sympathoinhibitory EA treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sympathoinhibitory EA treatment
Number of subjects: 21
Study: 33065060

Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg)
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study: 34308900

Group type: EXPERIMENTAL
Intervention: e-Health intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual home program (control)
Number of subjects: 0
Study: 33221865

Group type: EXPERIMENTAL
Intervention: Cross-lagged twin-differences analyses
Number of subjects: 2386

Group type: EXPERIMENTAL
Intervention: Polygenic score (PS) analyses
Number of subjects: 2386

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) analyses
Number of subjects: 2386

Group type: EXPERIMENTAL
Intervention: Multivariable MR
Number of subjects: 2386
Study: 32406767

Group type: EXPERIMENTAL
Intervention: Verbal and visual demonstrations on OFSP-based foods
Number of subjects: 764

Group type: COMPARATOR
Intervention: Verbal demonstrations on OFSP-based foods
Number of subjects: 764
Study: 33118636

Group type: EXPERIMENTAL
Intervention: Edoxaban (low-dose: 15 and 30 mg)
Number of subjects: 346
Study: 33152408

Group type: EXPERIMENTAL
Intervention: Two-unit cantilevered RBFPD (CL2)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Three-unit fixed-movable RBFPD (FM3)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (satisfaction and OHIP-49 scores) for both CL2 and FM3
Number of subjects: 83
Study: 32887548

Group type: EXPERIMENTAL
Intervention: Fremanezumab (quarterly or monthly)
Number of subjects: 1842

Group type: EXPERIMENTAL
Intervention: Fremanezumab
Number of subjects: 1842
Study: 33358708

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Photobiomodulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32972868

Group type: EXPERIMENTAL
Intervention: Health coaching intervention (3 telephonic calls by an unlicensed, trained health coach)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study: 34118115

Group type: EXPERIMENTAL
Intervention: 100 mg DPV ring
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 200 mg DPV ring
Number of subjects: 49

Group type: COMPARATOR
Intervention: Monthly 25 mg DPV ring
Number of subjects: 49
Study: 616738771

Group type: EXPERIMENTAL
Intervention: Immunization training intervention (two-day training)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 70
Study: 35260544

Group type: EXPERIMENTAL
Intervention: Low-fidelity simulator group (LFSG)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Video training group (VTG)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 121
Study: 35099430

Group type: EXPERIMENTAL
Intervention: Mulligan mobilisation with movement
Number of subjects: 64

Group type: COMPARATOR
Intervention: Muscle energy technique
Number of subjects: 64
Study: 34518109

Group type: EXPERIMENTAL
Intervention: Telephone counseling based on the IMB model
Number of subjects: 63

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 63
Study: 32028780

Group type: EXPERIMENTAL
Intervention: Sluggish cognitive tempo assessment
Number of subjects: 57
Study: 34967126

Group type: EXPERIMENTAL
Intervention: Low-sodium salt (LS) substitution
Number of subjects: 352

Group type: COMPARATOR
Intervention: Normal salt (NS)
Number of subjects: 352
Study: 34344273

Group type: EXPERIMENTAL
Intervention: Standardized educational intervention on cancer pain management and analgesics (10-15 minutes)
Number of subjects: 100
Study: 35395427

Group type: COMPARATOR
Intervention: Conservative management (n = 81)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Curative treatment (n = 78)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (17 patients)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Surgery (2 patients)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: RCT comparing endovascular with surgical treatment (20 patients)
Number of subjects: 403
Study: 33181169

Group type: EXPERIMENTAL
Intervention: Transcutaneous application of gaseous CO2 (CO2 therapy) for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo treatment with transcutaneous application of air for 4 weeks
Number of subjects: 42
Study: 36216918

Group type: EXPERIMENTAL
Intervention: Upper eyelid blepharoplasty (UEB) surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dermatochalasis (DC)
Number of subjects: 90
Study: 36102914

Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33464301

Group type: EXPERIMENTAL
Intervention: Motor Skill Training in Functional Activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strength and Flexibility Exercise
Number of subjects: 0
Study: 33379253

Group type: EXPERIMENTAL
Intervention: LGIMD plus PA1
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: LGIMD plus PA2
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 144
Study: 35057599

Group type: EXPERIMENTAL
Intervention: Tofacitinib (10 mg for 14 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of Care (SOC) treatment alone
Number of subjects: 100
Study: 32134320

Group type: EXPERIMENTAL
Intervention: weekly written feedback individualized by a counselor
Number of subjects: 1089

Group type: COMPARATOR
Intervention: automated and fully standardized feedback
Number of subjects: 1089
Study: 35486012

Group type: EXPERIMENTAL
Intervention: Eye acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined treatment (eye acupuncture + exercise therapy)
Number of subjects: 90
Study: 34544182

Group type: EXPERIMENTAL
Intervention: Lactate-guided therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normalizing capillary refill time
Number of subjects: 0
Study: 33561963

Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D supplementation (initial dose of 200,000 IU vitamin D3 followed by 100,000 IU monthly)
Number of subjects: 775

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D supplementation
Number of subjects: 775
Study: 32151236

Group type: EXPERIMENTAL
Intervention: Robotic therapy (ReoGeo system) plus standard therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Self-guided therapy plus standard therapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Robotic therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Self-guided therapy
Number of subjects: 56
Study: 35074433

Group type: EXPERIMENTAL
Intervention: DWI-guided dose-painting intensity modulated radiation therapy (DP-IMRT)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Conventional MRI-based IMRT
Number of subjects: 260
Study: 33627312

Group type: EXPERIMENTAL
Intervention: Screening by clinical breast examination (4 rounds every 2 years)
Number of subjects: 151538

Group type: EXPERIMENTAL
Intervention: Screening by clinical breast examination
Number of subjects: 151538
Study: 36310299

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: COMPARATOR
Intervention: Site assessments
Number of subjects: 147

Group type: COMPARATOR
Intervention: Post-progression unblinding
Number of subjects: 147
Study: 34536601

Group type: EXPERIMENTAL
Intervention: Nodal regression system (Tsekrekos grading)
Number of subjects: 47
Study: 35566482

Group type: EXPERIMENTAL
Intervention: Intravenous Ferric Carboxymaltose (FCM)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control
Number of subjects: 110
Study: 34419615

Group type: EXPERIMENTAL
Intervention: ECGio (artificial intelligence algorithm)
Number of subjects: 1659
Study: 32298131

Group type: EXPERIMENTAL
Intervention: Bridge-Enhanced ACL Repair (BEAR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Autograft ACL Reconstruction (ACLR)
Number of subjects: 100
Study: 35465014

Group type: EXPERIMENTAL
Intervention: Rehabilitation nursing under the guidance of the HAPA model
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 200
Study: 34292204

Group type: EXPERIMENTAL
Intervention: 50 mg of oral naltrexone (n = 42)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 82
Study: 32703511

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 2521

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 2521
Study: 34160113

Group type: EXPERIMENTAL
Intervention: Fermented rapeseed meal (FRSM)
Number of subjects: 420

Group type: COMPARATOR
Intervention: 15% Raw rapeseed meal (RRSM)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Fermented rapeseed meal (FRSM) and Raw rapeseed meal (RRSM)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 10% Fermented rapeseed meal (FRSM) and 10% Raw rapeseed meal (RRSM)
Number of subjects: 420
Study: 33098212

Group type: EXPERIMENTAL
Intervention: Simultaneous pump and CGM initiation offering low glucose suspend (LGS)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard pump therapy with CGM initiation delayed for 6 months
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: CGM adherence
Number of subjects: 144
Study: 33275819

Group type: EXPERIMENTAL
Intervention: Selegiline and symptomatic treatment for iRBD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Symptomatic treatment only (Control)
Number of subjects: 30
Study: 33232855

Group type: EXPERIMENTAL
Intervention: External focus (EF) instruction
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ankle bracing
Number of subjects: 19
Study: 35150818

Group type: EXPERIMENTAL
Intervention: Barberry group (10 g/day dried purple-black barberry powder, once daily for 2 months)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 84
Study: 32443950

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Exposure for PAP-associated Claustrophobia
Number of subjects: 0
Study: 32164669

Group type: EXPERIMENTAL
Intervention: Training home care teams on interprofessional shared decision-making (IP-SDM)
Number of subjects: 271
Study: 35930740

Group type: EXPERIMENTAL
Intervention: Informed consent language with none of GINA's limitations highlighted
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Informed consent language with various gaps in GINA highlighted
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: Informed consent language with the most information about limitations
Number of subjects: 1195
Study: 32969197

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LS) with cognitive behavioral therapy, nutrition advice, and exercise
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LS) with cognitive behavioral therapy, nutrition advice, exercise, and SMS
Number of subjects: 183

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 183
Study: 35780511

Group type: EXPERIMENTAL
Intervention: Treatment completers
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Elevated autistic characteristics
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High autistic characteristics
Number of subjects: 59
Study: 615918992

Group type: COMPARATOR
Intervention: Transcorneal electrical stimulation (TES) at 150% of individual EPTs, n = 15
Number of subjects: 52

Group type: COMPARATOR
Intervention: Transcorneal electrical stimulation (TES) at 200% of individual EPTs, n = 17
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham stimulation, n = 20
Number of subjects: 52
Study: 33962565

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose 0.6 µg/kg in 10 min before anaesthesia induction, followed by continuous infusion 0.5 µg/kg/hr until 1 hour before end of surgery)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Control (volume-matched normal saline)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 609

Group type: COMPARATOR
Intervention: Control
Number of subjects: 609
Study: 32558989

Group type: EXPERIMENTAL
Intervention: Danicamtiv (50–100 mg twice daily for 7 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33050719

Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic care + enhanced usual care (MCC+)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 61
Study: 32416406

Group type: EXPERIMENTAL
Intervention: Running training intervention for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study: 34569487

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BP-NLX)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: XR-NTX
Number of subjects: 153
Study: 32487222

Group type: EXPERIMENTAL
Intervention: Social media use disorder
Number of subjects: 456

Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 456

Group type: COMPARATOR
Intervention: Secondary level of education
Number of subjects: 456

Group type: COMPARATOR
Intervention: Higher social media use disorder
Number of subjects: 456

Group type: COMPARATOR
Intervention: Higher insomnia
Number of subjects: 456

Group type: COMPARATOR
Intervention: Higher alexithymia
Number of subjects: 456
Study: 36429859

Group type: EXPERIMENTAL
Intervention: Multicomponent group-based exercise program (6-9 weeks)
Number of subjects: 200
Study: 33972404

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 35578822

Group type: EXPERIMENTAL
Intervention: Stabilized hypochlorous acid solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (sterile 0.9% NaCl) solution
Number of subjects: 20
Study: 32141834

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker (Fitbit Flex)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Social media (Facebook)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Wearable activity trackers and social media
Number of subjects: 124
Study: 35034017

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with adjuvant chemotherapy (AC)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) without adjuvant chemotherapy (AC)
Number of subjects: 139
Study: 33942566

Group type: COMPARATOR
Intervention: PN-943, 100 to 1400 mg (single doses)
Number of subjects: 57

Group type: COMPARATOR
Intervention: PN-943, 100 to 1000 mg (multiple doses)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 450 mg PN-943 (twice daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: PN-943 after a high-fat meal
Number of subjects: 57

Group type: COMPARATOR
Intervention: PN-943 (multiple doses)
Number of subjects: 57

Group type: COMPARATOR
Intervention: PN-943 (single and multiple doses)
Number of subjects: 57
Study: 32044319

Group type: EXPERIMENTAL
Intervention: 3 mg upadacitinib twice daily
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 6 mg upadacitinib twice daily
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 12 mg upadacitinib twice daily
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 24 mg upadacitinib twice daily
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 24 mg upadacitinib once daily
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 33388813

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the left angular gyrus (AG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left angular gyrus (AG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 32687741

Group type: EXPERIMENTAL
Intervention: Prasugrel (reduced dose in elderly or low-weight group)
Number of subjects: 3997

Group type: COMPARATOR
Intervention: Ticagrelor (standard dose)
Number of subjects: 3997

Group type: EXPERIMENTAL
Intervention: Prasugrel (reduced dose in neither elderly nor low-weight group)
Number of subjects: 3997
Study: 35502136

Group type: EXPERIMENTAL
Intervention: Most positive stride width tertile
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Stride width of pitchers with meniscal injury
Number of subjects: 199

Group type: COMPARATOR
Intervention: Stride width
Number of subjects: 199
Study: 34267106

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HIIT vs MIIT
Number of subjects: 45
Study: 32960514

Group type: EXPERIMENTAL
Intervention: Insulin icodec
Number of subjects: 247

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 247
Study: 35710576

Group type: EXPERIMENTAL
Intervention: bDMARD tapering according to a strategy that combines disease activity guided dose optimization (DGDO) with a dynamic flare prediction model.
Number of subjects: 160

Group type: COMPARATOR
Intervention: disease activity guided dose optimization (DGDO)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: bDMARD tapering according to a strategy that combines DGDO with the dynamic flare prediction model.
Number of subjects: 160
Study: 33648940

Group type: EXPERIMENTAL
Intervention: Polyphenon E (780 mg EGCG daily for 6 months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 32677772

Group type: EXPERIMENTAL
Intervention: GnRH agonist (diphereline) at two doses, 8 weeks before endometrial preparation
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard treatment with estradiol valerate (6-8 mg/day)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: GnRH agonist (diphereline)
Number of subjects: 178
Study: 36161540

Group type: EXPERIMENTAL
Intervention: eAsthmaCare online management
Number of subjects: 98

Group type: COMPARATOR
Intervention: General asthma management (Control)
Number of subjects: 98
Study: 33309349

Group type: EXPERIMENTAL
Intervention: Flunixin meglumine (FLU) 2.2 mg/kg i.v. and whey protein placebo orally
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Meloxicam (MEL) 1 mg/kg orally and 2 mL/45 kg sterile saline placebo i.v.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (LAME + PLBO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (SHAM + PLBO)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flunixin meglumine (FLU)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Meloxicam (MEL)
Number of subjects: 48
Study: 34689702

Group type: EXPERIMENTAL
Intervention: Saline + Rifampicin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Saline + 10% Povidone-Iodine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Perioperative Blood Transfusion
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Midline Incision
Number of subjects: 300